Rigel Pharmaceuticals, Inc. (RIGL): Price and Financial Metrics


Rigel Pharmaceuticals, Inc. (RIGL): $3.24

-0.04 (-1.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RIGL POWR Grades


  • Value is the dimension where RIGL ranks best; there it ranks ahead of 94.84% of US stocks.
  • RIGL's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • RIGL ranks lowest in Momentum; there it ranks in the 9th percentile.

RIGL Stock Summary

  • The price/operating cash flow metric for Rigel Pharmaceuticals Inc is higher than 99.84% of stocks in our set with a positive cash flow.
  • For RIGL, its debt to operating expenses ratio is greater than that reported by merely 20.96% of US equities we're observing.
  • Revenue growth over the past 12 months for Rigel Pharmaceuticals Inc comes in at 33.4%, a number that bests 79.56% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to RIGL, based on their financial statements, market capitalization, and price volatility, are ALLT, GEOS, CYRN, MRIN, and SMSI.
  • RIGL's SEC filings can be seen here. And to visit Rigel Pharmaceuticals Inc's official web site, go to www.rigel.com.

RIGL Valuation Summary

  • In comparison to the median Healthcare stock, RIGL's price/sales ratio is 60.35% lower, now standing at 4.5.
  • RIGL's price/sales ratio has moved down 11.1 over the prior 243 months.
  • RIGL's EV/EBIT ratio has moved down 148 over the prior 243 months.

Below are key valuation metrics over time for RIGL.

Stock Date P/S P/B P/E EV/EBIT
RIGL 2021-08-31 4.5 9.5 -84.0 -156.5
RIGL 2021-08-30 4.5 9.5 -84.0 -156.5
RIGL 2021-08-27 4.5 9.6 -84.6 -157.9
RIGL 2021-08-26 4.4 9.3 -82.2 -153.0
RIGL 2021-08-25 4.5 9.5 -83.3 -155.2
RIGL 2021-08-24 4.4 9.4 -82.4 -153.4

RIGL Growth Metrics

  • Its 5 year price growth rate is now at -13.66%.
  • The 3 year cash and equivalents growth rate now stands at 423.48%.
  • Its 4 year price growth rate is now at -28.47%.
Over the past 67 months, RIGL's revenue has gone up $115,228,000.

The table below shows RIGL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 144.123 0.207 -7.732
2021-03-31 133.878 -69.047 -11.487
2020-12-31 108.621 -52.185 -29.744
2020-09-30 105.571 -46.262 -27.707
2020-06-30 108.039 -41.421 -25.023
2020-03-31 102.425 -44.034 -28.053

RIGL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RIGL has a Quality Grade of B, ranking ahead of 89.82% of graded US stocks.
  • RIGL's asset turnover comes in at 0.886 -- ranking 27th of 680 Pharmaceutical Products stocks.
  • SBBP, CSBR, and NSTG are the stocks whose asset turnover ratios are most correlated with RIGL.

The table below shows RIGL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.886 0.994 -0.034
2021-03-31 0.912 0.992 -0.069
2020-12-31 0.844 0.992 -0.296
2020-09-30 0.765 0.993 -0.259
2020-06-30 0.739 0.991 -0.220
2020-03-31 0.679 0.991 -0.249

RIGL Price Target

For more insight on analysts targets of RIGL, see our RIGL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.33 Average Broker Recommendation 1.33 (Strong Buy)

RIGL Stock Price Chart Interactive Chart >

Price chart for RIGL

RIGL Price/Volume Stats

Current price $3.24 52-week high $5.50
Prev. close $3.28 52-week low $2.36
Day low $3.19 Volume 1,500,100
Day high $3.25 Avg. volume 2,479,217
50-day MA $3.68 Dividend yield N/A
200-day MA $3.86 Market Cap 553.55M

Rigel Pharmaceuticals, Inc. (RIGL) Company Bio


Rigel Pharmaceuticals, Inc. engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. The company was founded in 1996 and is based in South San Francisco, California.


RIGL Latest News Stream


Event/Time News Detail
Loading, please wait...

RIGL Latest Social Stream


Loading social stream, please wait...

View Full RIGL Social Stream

Latest RIGL News From Around the Web

Below are the latest news stories about Rigel Pharmaceuticals Inc that investors may wish to consider to help them evaluate RIGL as an investment opportunity.

Rigel to Participate in Three Upcoming Investor Conferences

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following virtual investor conferences in September:

Yahoo | September 2, 2021

Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in Clinical Infectious Diseases, an official publication of the Infectious Disease Society of America. The study was sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), in collaboration with Inova Health System.

Yahoo | September 1, 2021

Thrombopoietin Receptor Agonist Market Significantly Stepping towards the Success Till 2027| Amgen, Novartis, Rigel Pharmaceuticals

Prior to the widespread availability of thrombopoietin receptor agonists (TPO-RA), splenectomy and rituximab were the most prevalent second-line therapies for patients with immunological thrombocytopenia (ITP). Both approaches have the potential to cure the disease. Long-term answers, on the other hand,

OpenPR | August 27, 2021

Why Did the FDA Reject Rigel's EUA Application for Its COVID-19 Therapy?

Rigel Pharmaceuticals (NASDAQ: RIGL) recently received a thumbs-down from the Food and Drug Administration for an EUA filing for its COVID therapeutic candidate. In this Motley Fool Live video recorded on Aug. 18, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why the FDA turned down an EUA for Rigel's experimental COVID therapy.

Yahoo | August 26, 2021

Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations

Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.

Yahoo | August 18, 2021

Read More 'RIGL' Stories Here

RIGL Price Returns

1-mo -16.71%
3-mo -21.36%
6-mo -16.92%
1-year 31.71%
3-year 18.68%
5-year 24.62%
YTD -7.43%
2020 63.55%
2019 -6.96%
2018 -40.72%
2017 63.03%
2016 -21.45%

Continue Researching RIGL

Here are a few links from around the web to help you further your research on Rigel Pharmaceuticals Inc's stock as an investment opportunity:

Rigel Pharmaceuticals Inc (RIGL) Stock Price | Nasdaq
Rigel Pharmaceuticals Inc (RIGL) Stock Quote, History and News - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.845 seconds.